Description
EMPAMET XR offers advanced, once-daily combination therapy for adults with type 2 diabetes. This extended-release medication combines Empagliflozin, an SGLT2 inhibitor, with Metformin Hydrochloride (extended-release). Empagliflozin works by helping your kidneys remove excess glucose from your body through urine, while Metformin reduces glucose production by the liver and improves the body’s sensitivity to insulin. The extended-release formulation of Metformin contributes to better gastrointestinal tolerability and convenient once-daily dosing. Beyond effective blood sugar control, EMPAMET XR is also indicated to significantly reduce the risk of cardiovascular death, hospitalization for heart failure, and the progression of chronic kidney disease in eligible patients. Used alongside diet and exercise, it provides comprehensive support for long-term diabetes management.
